Free tool
FAERS Monitor: Vyndamax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212161 or its brand name (Vyndamax, Tafamidis). Reports on generic versions are filed under their own applications.
Reports
12,176
Serious
9,441
78% of reports
Hospitalization
3,429
Death reported
4,214
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,266
- dyspnoea804
- off label use661
- cardiac failure638
- fatigue585
- fall479
- atrial fibrillation397
- dizziness357
- malaise349
- asthenia332
- condition aggravated311
- cardiac failure congestive308
- hypoacusis303
- weight decreased302
- cardiac disorder288
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 123 |
| 2020 | 644 |
| 2021 | 1,043 |
| 2022 | 1,755 |
| 2023 | 2,500 |
| 2024 | 2,545 |
| 2025 | 2,110 |
| 2026 | 1,447 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,983 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac failureSignal | 638 | 13.8 | 12.8 | 7,549 |
| hypoacusisSignal | 303 | 12.2 | 10.9 | 3,100 |
| atrial fibrillationSignal | 397 | 7.1 | 6.4 | 2,063 |
| cardiac failure congestiveSignal | 308 | 6.6 | 5.9 | 1,471 |
| deathSignal | 3,266 | 6.6 | 6.4 | 16,014 |
| cardiac disorderSignal | 288 | 5.3 | 4.8 | 1,010 |
| fallSignal | 479 | 2.5 | 2.3 | 431 |
| dyspnoeaSignal | 804 | 2.5 | 2.3 | 710 |
| weight decreased | 302 | 1.9 | 1.7 | 123 |
| condition aggravated | 311 | 1.8 | 1.6 | 104 |
| asthenia | 332 | 1.5 | 1.4 | 61 |
| malaise | 349 | 1.4 | 1.2 | 36 |
| off label use | 661 | 1.3 | 1.2 | 49 |
| fatigue | 585 | 1.3 | 1.2 | 41 |
| dizziness | 357 | 1.2 | 1.1 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.